{"id":447,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/pt-br\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","title":{"rendered":"Tirzepatide Sinaliza\u00e7\u00e3o dupla GIP\/GLP-1: mecanismo e pontos finais de teste explicados"},"content":{"rendered":"
Tirzepatide \u00e9 um pept\u00eddeo acilado projetado para ativar tanto o receptor do polipept\u00eddeo insulinotr\u00f3pico dependente de glicose (GIP) quanto o receptor do pept\u00eddeo semelhante ao glucagon-1 (GLP-1). Compreender que a farmacologia dupla requer a separa\u00e7\u00e3o da atividade do receptor dos resultados cl\u00ednicos medidos em popula\u00e7\u00f5es espec\u00edficas.<\/p>
Principais conclus\u00f5es<\/h2>
Tirzepatide \u00e9 um agonista duplo do receptor GIP \/ GLP-1, n\u00e3o um \u201cagonista triplo\u201d.<\/li>
Os ensaios SURPASS focaram nos resultados do diabetes tipo 2; Os ensaios SURMOUNT focaram nos resultados relacionados \u00e0 obesidade.<\/li>
Os dados de medicamentos acabados aprovados pela FDA n\u00e3o estabelecem qualidade, seguran\u00e7a ou efic\u00e1cia para um material de cat\u00e1logo de uso em pesquisa n\u00e3o relacionado.<\/li><\/ul><\/div><\/div>Ilustra\u00e7\u00e3o editorial original da pesquisa de pept\u00eddeos multirreceptores. \u00c9 uma cena conceitual de laborat\u00f3rio, n\u00e3o uma imagem de produto ou tratamento.<\/figcaption><\/figure>
O que significa agonismo de receptor duplo<\/h2>
GIP e GLP-1 s\u00e3o sistemas de sinaliza\u00e7\u00e3o responsivos a nutrientes com a\u00e7\u00f5es sobrepostas e distintas. Tirzepatide foi concebido como uma mol\u00e9cula capaz de ativar ambos os receptores. O efeito cl\u00ednico \u00e9 o resultado da farmacologia, exposi\u00e7\u00e3o e formula\u00e7\u00e3o de toda a mol\u00e9cula; n\u00e3o pode ser inferido simplesmente adicionando duas descri\u00e7\u00f5es de caminhos separados.<\/p>
O r\u00f3tulo FDA identifica a tirzepatida como o ingrediente ativo de produtos de prescri\u00e7\u00e3o aprovados e descreve indica\u00e7\u00f5es, advert\u00eancias e detalhes de formula\u00e7\u00e3o espec\u00edficos do produto. Essas declara\u00e7\u00f5es pertencem ao medicamento acabado aprovado e indicado no r\u00f3tulo.<\/p>
Como ler os programas de teste<\/h2>
SURPASS-1 foi um estudo de fase randomizado 3 em adultos com diabetes tipo 2 inadequadamente controlados por dieta e exerc\u00edcios. Seu desfecho prim\u00e1rio foi a altera\u00e7\u00e3o na hemoglobina glicada, com peso corporal e seguran\u00e7a entre os desfechos adicionais. O SURMOUNT-1 inscreveu adultos com obesidade ou sobrepeso, al\u00e9m de uma condi\u00e7\u00e3o relacionada ao peso, e usou a varia\u00e7\u00e3o percentual no peso corporal como desfecho prim\u00e1rio.<\/p>
Popula\u00e7\u00e3o, comparador, dura\u00e7\u00e3o do tratamento, estimativa e tratamento da descontinua\u00e7\u00e3o afetam a interpreta\u00e7\u00e3o. A porcentagem do t\u00edtulo nunca deve ser separada desses elementos de design.<\/p>
SURPASS-1<\/strong>Fase 3, diabetes tipo 2, desfecho prim\u00e1rio de controle glic\u00eamico<\/span><\/div>
SURMOUNT-1<\/strong>Fase 3, popula\u00e7\u00e3o com obesidade\/excesso de peso, desfecho prim\u00e1rio de peso corporal<\/span><\/div>
Registro regulat\u00f3rio<\/strong>Informa\u00e7\u00f5es de prescri\u00e7\u00e3o e linguagem de seguran\u00e7a espec\u00edficas do produto FDA<\/span><\/div><\/div><\/div>
Por que a equival\u00eancia material \u00e9 importante<\/h2>
Os resultados dos ensaios cl\u00ednicos aplicam-se \u00e0 interven\u00e7\u00e3o estudada, fabricada e controlada nas condi\u00e7\u00f5es desse ensaio. A identidade da sequ\u00eancia por si s\u00f3 n\u00e3o demonstra equival\u00eancia em pureza, agrega\u00e7\u00e3o, contra-\u00edon, esterilidade, carga particulada, formula\u00e7\u00e3o ou estabilidade.<\/p>
Para material de pesquisa de cat\u00e1logo, os pesquisadores devem confiar nas especifica\u00e7\u00f5es espec\u00edficas do produto e na documenta\u00e7\u00e3o do lote. As alega\u00e7\u00f5es cl\u00ednicas de um medicamento aprovado n\u00e3o devem ser transferidas para uma p\u00e1gina de produto para uso em pesquisa.<\/p>","protected":false},"excerpt":{"rendered":"
Uma explica\u00e7\u00e3o baseada em evid\u00eancias sobre o agonismo do receptor duplo da tirzepatida e os desfechos medidos nos ensaios SURPASS e SURMOUNT, com limites claros na aplica\u00e7\u00e3o de dados de medicamentos para catalogar materiais.<\/p>","protected":false},"author":1,"featured_media":617,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"370","pim_article_type":"Clinical evidence explainer","pim_evidence_level":"Randomized phase 3 trials and FDA labeling","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-27","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"SURPASS-1 randomized phase 3 trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34186022\/\",\"note\":\"Primary clinical trial record; PMID 34186022.\"},{\"title\":\"SURMOUNT-1 obesity trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35658024\/\",\"note\":\"Primary clinical trial record; PMID 35658024.\"},{\"title\":\"FDA prescribing information for Mounjaro (tirzepatide)\",\"url\":\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215866s039lbl.pdf\",\"note\":\"Approved-finished-product regulatory record.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-447","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"\n
Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained - NHD<\/title>\n<meta name=\"description\" content=\"An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data to catalog materials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/pt-br\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained\" \/>\n<meta property=\"og:description\" content=\"An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data to catalog materials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/pt-br\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Tirzepatide Dual GIP\\\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\"},\"wordCount\":369,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\",\"name\":\"Tirzepatide Dual GIP\\\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data to catalog materials.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tirzepatide Dual GIP\\\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/pt-br\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tirzepatide Sinaliza\u00e7\u00e3o dupla GIP\/GLP-1: mecanismo e pontos finais de teste explicados - NHD","description":"Uma explica\u00e7\u00e3o baseada em evid\u00eancias sobre o agonismo do receptor duplo da tirzepatida e os desfechos medidos nos ensaios SURPASS e SURMOUNT, com limites claros na aplica\u00e7\u00e3o de dados de medicamentos para catalogar materiais.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/pt-br\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","og_locale":"pt_BR","og_type":"article","og_title":"Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained","og_description":"An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data to catalog materials.","og_url":"https:\/\/nhdbio.com\/pt-br\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Est. tempo de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/"},"wordCount":369,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","url":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","name":"Tirzepatide Sinaliza\u00e7\u00e3o dupla GIP\/GLP-1: mecanismo e pontos finais de teste explicados - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"Uma explica\u00e7\u00e3o baseada em evid\u00eancias sobre o agonismo do receptor duplo da tirzepatida e os desfechos medidos nos ensaios SURPASS e SURMOUNT, com limites claros na aplica\u00e7\u00e3o de dados de medicamentos para catalogar materiais.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mat\u00e9rias-primas pept\u00eddicas e s\u00edntese personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipe T\u00e9cnica NHD","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"A equipe t\u00e9cnica NHD mant\u00e9m documenta\u00e7\u00e3o de cat\u00e1logo de uso em pesquisa e resumos de evid\u00eancias. Os artigos revisados \u200b\u200bvinculam-se a artigos revisados \u200b\u200bpor pares, registros de ensaios e registros regulat\u00f3rios, ret\u00eam resultados nulos e limita\u00e7\u00f5es de estudos e distinguem interven\u00e7\u00f5es publicadas de materiais de cat\u00e1logo. O desenho assistido por AI pode ser usado para estrutura; os links de origem e os limites das evid\u00eancias permanecem vis\u00edveis. Este trabalho n\u00e3o \u00e9 uma revis\u00e3o independente por pares ou aconselhamento m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/pt-br\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/comments?post=447"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/447\/revisions"}],"predecessor-version":[{"id":524,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/447\/revisions\/524"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media\/617"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media?parent=447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/categories?post=447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/tags?post=447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Pesquisador](\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/metabolic-peptide-receptor-research.png\")